Asset Details
Do you wish to reserve the book?
Chloroquine for COVID-19: rationale, facts, hopes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Chloroquine for COVID-19: rationale, facts, hopes
Do you wish to request the book?
Chloroquine for COVID-19: rationale, facts, hopes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Chloroquine for COVID-19: rationale, facts, hopes
2020
Overview
Several mechanisms have been proposed to assume that CQ or hydroxychloroquine (HCQ) may be effective against SARS-CoV-2 (Fig. 1) [1, 2]: 1. a) Cell models of SARS-CoV-1 infection treated with CQ show interference with the glycosylation of ACE-2 receptors, proposed as the site of SARS-CoV-2 cell binding. 2. b) CQ/HCQ increases the pH of acidic cellular organelles, hindering the intermediate stages of endocytosis and virion transport and post-translational modification of newly synthesized viral proteins. 3. c) CQ/HCQ can counter the process of virion assembly and viral protein synthesis. [...]the indications for combined HCQ-azithromycin treatment were not described. On April 3, the International Society of Antimicrobial Chemotherapy (ISAC) declared that “The ISAC Board believes the article does not meet the Society’s expected standard, especially relating to the lack of better explanations of the inclusion criteria and the triage of patients to ensure patient safety.” highlighting that “the need for fast release of new data should not reduce the quality of scientific scrutiny” [8].
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Antimalarials - pharmacology
/ Antimalarials - therapeutic use
/ Antiviral Agents - pharmacology
/ Antiviral Agents - therapeutic use
/ Betacoronavirus - drug effects
/ Chloroquine - therapeutic use
/ Coronavirus Infections - drug therapy
/ COVID-19
/ Drugs
/ Humans
/ Medicine
/ Pneumonia, Viral - drug therapy
/ Sepsis
